News|Articles|November 22, 2026

Glucose Data: How Pharmacists Turn Readings Into Next Steps

Listen
0:00 / 0:00

Key Takeaways

  • Pharmacists can move patients from reacting to single glucose values toward recognizing reproducible daily patterns and correlating excursions with diet, activity, and medication timing.
  • CGM data support near-real-time education on how lifestyle and pharmacotherapy affect glycemia, but benefits depend on correct data review and interpretation.
SHOW MORE

Brooke Hudspeth, Nicole Paolini Albanese, and Joshua Neumiller explain how pharmacists spot patterns, fix testing problems, and brief the care team.

Glucose data only improve diabetes care when someone acts on them. Pharmacists are in a position to spot problems in a log or report, sort out the cause, and get a clear summary to the prescriber before the next visit.

"Ultimately, I think we want that monitoring to lead to an action," said Brooke Hudspeth, PharmD, associate dean of pharmacy practice at the University of Kentucky College of Pharmacy, in an interview with Pharmacy Times. "Maybe it's reinforcing something that's working, so it doesn't always have to result in a change."

Finding the Pattern

The first step is moving patients past individual readings. Pharmacists, Hudspeth said, "are really trained to help patients ask what pattern they're seeing with those numbers." She described a patient whose readings run high at the same time each afternoon: "Every day at 4 o'clock in the afternoon, they're getting elevated blood glucose readings, and we're seeing that day after day."

Pharmacists can then look at what drives the pattern, including food, physical activity, medications, and medication timing, she said.

Continuous glucose monitoring (CGM) makes this easier to show. In a separate interview with Pharmacy Times, Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, senior vice president of medical affairs at the American Diabetes Association (ADA), said CGM "has particularly impacted how pharmacists can support people with diabetes on a daily basis through using data to educate people about how their medications, how their physical activity and lifestyle, and other factors impact their blood glucose." Whatever the data source, the ADA notes that optimal use of monitoring "requires proper review and interpretation of data."1

Troubleshooting Before Escalating

Not every bad number calls for more medication. Some technique problems are easy to fix "if we just watched the patient go through the process," Hudspeth said. One of her patients reported that testing was painful and frustrating. When she demonstrated her technique at the pharmacy, Hudspeth found she was skipping the lancing device. "She was actually taking the lancet itself and essentially jabbing it directly into her finger."

A simpler device solved the problem. "Sometimes we assume a patient is just not adherent," Hudspeth explained. "But the real problem, I learned, was that we hadn't given her the right tools."

Device factors deserve the same scrutiny. The ADA lists expired or improperly stored test strips, abnormal hematocrit, and low oxygen tension, such as at high altitude, among factors that can distort meter readings. For CGM, patients should rely on a meter while a sensor warms up; some medications, including acetaminophen and vitamin C at certain doses depending on the sensor, can falsely raise sensor values, and adhesive reactions are worth asking about periodically.1

Handing Off to the Care Team

The next step is to make the data usable for the prescriber. Nicole Paolini Albanese, PharmD, CDCES, BCACP, a clinical associate professor at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences, said context is what protects patients from unnecessary changes. Without it, she said, a prescriber might look at a log and say, "You had this one 200, and you're always 100. We need to increase your medication," when that may not be the case.

Albanese said a patient who can explain an outlier, such as "This was an outlier because I was out the night before and I had a bottle of wine," gives the provider a more accurate picture. The pharmacist is there to educate on that so that they can have a good conversation then with their provider, she said.

In some practices, pharmacists can go further. Collaborative practice agreements allow pharmacists to assume increased responsibility, such as initiating, modifying, or discontinuing drug therapy under an agreement with a provider.2

"We know that important gaps exist in use of evidence-based therapies in diabetes, and pharmacists are well positioned to intervene and address gaps related to education, care coordination, access to therapies and technologies, and optimization of guideline-directed therapy," Neumiller said. He sees pharmacists "positioned as a central member of the care team, regardless of practice setting."

REFERENCES
1. American Diabetes Association Professional Practice Committee for Diabetes. 7. Diabetes technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S150-S165. doi:10.2337/dc26-S007
2. Hamilton AL, Darr M. Louisiana state policies prove problematic for pharmacist–physician collaboration. Prev Chronic Dis. 2020;17:E89. Accessed November 18, 2026. https://stacks.cdc.gov/view/cdc/93365/cdc_93365_DS1.pdf

Related to this article